AMRUTANJAN493.35

Amrutanjan Health Care Limited

· Pharma & Health
₹ CrorePeersJAGSNPHARMNGLFINESIGACHILINCOLNSYNCOMFTHEMISMEDHESTERBIOMcap ₹1,426 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)102.0798.91128.10128.10
Receivable Days (DSO)41.5045.1044.0544.05
Payable Days (DPO)197.27250.51243.14233.23
Cash Conversion Cycle (days)-53.70-106.50-70.99-61.08
Working Capital Turnover1.872.193.043.09
Asset Turnover1.151.070.990.99
Cash Conversion (CFO/Net Income)0.621.000.620.62
CFO/EBITDA0.540.870.480.48
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.